Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in children

Asmaa Hachim, Haogao Gu, Otared Kavian, Mike YW Kwan, Wai-hung Chan, Yat Sun Yau, Susan S Chiu, Owen TY Tsang, David SC Hui, Fionn Ma, View ORCID ProfileEric HY Lau, Samuel MS Cheng, Leo LM Poon, JS Malik Peiris, Sophie A Valkenburg, Niloufar Kavian
doi: https://doi.org/10.1101/2021.01.03.21249180
Asmaa Hachim
1HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haogao Gu
2Division of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otared Kavian
3Department of Mathematics, Université de Versailles Saint-Quentin, Versailles, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike YW Kwan
4Department of Paediatric and Adolescent Medicine, Princess Margaret Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wai-hung Chan
5Department of Paediatrics, Queen Elizabeth Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yat Sun Yau
5Department of Paediatrics, Queen Elizabeth Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan S Chiu
6Department of Paediatric and Adolescent Medicine, The University of Hong Kong and Queen Mary Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Owen TY Tsang
7Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David SC Hui
8Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fionn Ma
1HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric HY Lau
9WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric HY Lau
Samuel MS Cheng
2Division of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo LM Poon
1HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
2Division of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JS Malik Peiris
1HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
2Division of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie A Valkenburg
1HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sophiev@hku.hk
Niloufar Kavian
1HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
10Faculté de Médecine Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique–Hôpitaux de Paris, Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire Cochin, Service d’Immunologie Biologique, Paris, France
11Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Children are less clinically affected by SARS-CoV-2 infection than adults with the majority of cases being mild or asymptomatic and the differences in infection outcomes are poorly understood. The kinetics, magnitude and landscape of the antibody response may impact the clinical severity and serological diagnosis of COVID-19. Thus, a comprehensive investigation of the antibody landscape in children and adults is needed.

Methods We tested 254 plasma from 122 children with symptomatic and asymptomatic SARS-CoV-2 infections in Hong Kong up to 206 days post symptom onset, including 146 longitudinal samples from 58 children. Adult COVID-19 patients and pre-pandemic controls were included for comparison. We assessed antibodies to a 14-wide panel of SARS-CoV-2 structural and accessory proteins by Luciferase Immunoprecipitation System (LIPS).

Findings Children have lower levels of Spike and Nucleocapsid antibodies than adults, and their cumulative humoral response is more expanded to accessory proteins (NSP1 and Open Reading Frames (ORFs)). Sensitive serology using the three N, ORF3b, ORF8 antibodies can discriminate COVID-19 in children. Principal component analysis revealed distinct serological signatures in children and the highest contribution to variance were responses to non-structural proteins ORF3b, NSP1, ORF7a and ORF8. Longitudinal sampling revealed maintenance or increase of antibodies for at least 6 months, except for ORF7b antibodies which showed decline. It was interesting to note that children have higher antibody responses towards known IFN antagonists: ORF3b, ORF6 and ORF7a. The diversified SARS-CoV-2 antibody response in children may be an important factor in driving control of SARS-CoV-2 infection.

Competing Interest Statement

A Hachim, N Kavian, LLM Poon, JSM Peiris and SA Valkenburg have filed an IDF (US 63/016,898) for the use of ORF8 and ORF3b as diagnostics of SARS-CoV-2 infection.

Funding Statement

This study was partly supported by the Theme based Research Grants Scheme (T11-712/19-N), Health and Medical Research Fund (HMRF COVID-190115 and COVID-190126), National Institutes of Allergy and Infectious Diseases, National Institutes of Health (USA) (contract HHSN272201400006C).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The COVID-19 patient study was approved by the institutional review board of the respective hospitals, viz. Kowloon West Cluster (KW/EX-20-039 (144-27)), Kowloon Central / Kowloon East cluster (KC/KE-20-0154/ER2) and HKU/HA Hong Kong West Cluster (UW 20-273, UW20-169), Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (CREC 2020.229). All of patients provided informed consent. The collection of plasma from blood donors serving as controls was approved by Institutional Review Board of The Hong Kong University and the Hong Kong Island West Cluster (UW16-254).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Author contributions A.H. and N.K. performed the experiments and analysed the data. H.G., O.K. and E.H.Y.L performed specialist statistical analysis. M.Y.W.K, W.H.C, Y.S.Y, S.S.C, O.T.Y.T, D.S.C.H and S.M.S.C provided clinical samples, which F.M processed. A.H., L.L.M.P., J.S.M.P., S.A.V. and N.K. designed the study, interpreted results and wrote the manuscript.

  • Author order

Data Availability

Data availability statement The data that support the findings of this study are available from the corresponding author upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 04, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in children
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in children
Asmaa Hachim, Haogao Gu, Otared Kavian, Mike YW Kwan, Wai-hung Chan, Yat Sun Yau, Susan S Chiu, Owen TY Tsang, David SC Hui, Fionn Ma, Eric HY Lau, Samuel MS Cheng, Leo LM Poon, JS Malik Peiris, Sophie A Valkenburg, Niloufar Kavian
medRxiv 2021.01.03.21249180; doi: https://doi.org/10.1101/2021.01.03.21249180
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in children
Asmaa Hachim, Haogao Gu, Otared Kavian, Mike YW Kwan, Wai-hung Chan, Yat Sun Yau, Susan S Chiu, Owen TY Tsang, David SC Hui, Fionn Ma, Eric HY Lau, Samuel MS Cheng, Leo LM Poon, JS Malik Peiris, Sophie A Valkenburg, Niloufar Kavian
medRxiv 2021.01.03.21249180; doi: https://doi.org/10.1101/2021.01.03.21249180

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (180)
  • Allergy and Immunology (435)
  • Anesthesia (99)
  • Cardiovascular Medicine (949)
  • Dentistry and Oral Medicine (178)
  • Dermatology (111)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (423)
  • Epidemiology (9018)
  • Forensic Medicine (4)
  • Gastroenterology (422)
  • Genetic and Genomic Medicine (1964)
  • Geriatric Medicine (191)
  • Health Economics (405)
  • Health Informatics (1333)
  • Health Policy (662)
  • Health Systems and Quality Improvement (522)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10832)
  • Intensive Care and Critical Care Medicine (576)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (223)
  • Neurology (1842)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (358)
  • Occupational and Environmental Health (470)
  • Oncology (1006)
  • Ophthalmology (299)
  • Orthopedics (111)
  • Otolaryngology (184)
  • Pain Medicine (126)
  • Palliative Medicine (45)
  • Pathology (267)
  • Pediatrics (583)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1910)
  • Public and Global Health (4137)
  • Radiology and Imaging (678)
  • Rehabilitation Medicine and Physical Therapy (370)
  • Respiratory Medicine (551)
  • Rheumatology (226)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (110)
  • Urology (82)